Differences in miRNA differential expression in whole blood between horses with sarcoid regression and progression.
equine cancer
equine sarcoid (ES) disease
high throughput sequencing
microRNA
prognostic biomarker
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
08
06
2018
accepted:
06
11
2018
pubmed:
7
12
2018
medline:
8
2
2019
entrez:
4
12
2018
Statut:
ppublish
Résumé
Currently no methods are available to predict the clinical outcome of individual horses with equine sarcoid (ES) disease. To investigate if whole blood microRNA (miRNA) profiles can predict the long-term development of ES tumors. Five horses with regression and 5 with progression of ES lesions monitored over 5-7 years and 5 control horses free of ES for at least 5 years. For this cohort study, RNA extracted from whole blood samples from the regression, progression, and control groups was used for high throughput sequencing. Known and novel miRNAs were identified using miRDeep2 and differential expression analysis was carried out by the DESeq2 algorithm. Target gene and pathway prediction as well as enrichment and network analyses were conducted using TarBase, mirPath, and metaCore from GeneGo. Fourteen miRNAs were differentially expressed between regression and progression groups after accounting for the control condition: 4 miRNAs (28.6%) were upregulated and 10 miRNAs (71.4%) were downregulated with >2-fold change. Seven of the 10 downregulated miRNAs are encoded in an miRNA cluster on equine chromosome 24, homologous to the well-known 14q32 cluster in humans. Their target genes show enrichment for pathways involved in viral carcinogenesis. Whole blood miRNA expression profiles are associated with long-term ES growth in horses and warrant further validation as prognostic biomarkers in a larger study cohort. Deregulation of miRNAs on equine chromosome 24 might represent a trigger for ES development.
Sections du résumé
BACKGROUND
BACKGROUND
Currently no methods are available to predict the clinical outcome of individual horses with equine sarcoid (ES) disease.
OBJECTIVE
OBJECTIVE
To investigate if whole blood microRNA (miRNA) profiles can predict the long-term development of ES tumors.
ANIMALS
METHODS
Five horses with regression and 5 with progression of ES lesions monitored over 5-7 years and 5 control horses free of ES for at least 5 years.
METHODS
METHODS
For this cohort study, RNA extracted from whole blood samples from the regression, progression, and control groups was used for high throughput sequencing. Known and novel miRNAs were identified using miRDeep2 and differential expression analysis was carried out by the DESeq2 algorithm. Target gene and pathway prediction as well as enrichment and network analyses were conducted using TarBase, mirPath, and metaCore from GeneGo.
RESULTS
RESULTS
Fourteen miRNAs were differentially expressed between regression and progression groups after accounting for the control condition: 4 miRNAs (28.6%) were upregulated and 10 miRNAs (71.4%) were downregulated with >2-fold change. Seven of the 10 downregulated miRNAs are encoded in an miRNA cluster on equine chromosome 24, homologous to the well-known 14q32 cluster in humans. Their target genes show enrichment for pathways involved in viral carcinogenesis.
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
Whole blood miRNA expression profiles are associated with long-term ES growth in horses and warrant further validation as prognostic biomarkers in a larger study cohort. Deregulation of miRNAs on equine chromosome 24 might represent a trigger for ES development.
Identifiants
pubmed: 30506726
doi: 10.1111/jvim.15375
pmc: PMC6335546
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241-250Subventions
Organisme : Swiss Institute Research Funds
ID : ismequine.ch
Organisme : Swiss Institute of Equine Medicine
Organisme : University of Bern
Organisme : Swiss Institute of Equine Medicine
Organisme : University of Bern
Informations de copyright
© 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Références
J Gen Virol. 2007 Aug;88(Pt 8):2155-2161
pubmed: 17622617
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Schweiz Arch Tierheilkd. 2012 Jan;154(1):19-25
pubmed: 22222899
Nucleic Acids Res. 2012 Jan;40(1):37-52
pubmed: 21911355
Int J Cancer. 2016 Aug 15;139(4):784-92
pubmed: 27037728
Genome Biol. 2007;8(1):R3
pubmed: 17204154
Genome Med. 2013 Jan 22;5(1):2
pubmed: 23339462
Cancer Prev Res (Phila). 2012 Mar;5(3):492-497
pubmed: 22158052
PLoS One. 2011;6(9):e24145
pubmed: 21909417
Anim Genet. 1994 Jun;25 Suppl 1:75-80
pubmed: 7943987
PLoS One. 2014 Apr 02;9(4):e93662
pubmed: 24695583
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
Clin Chem. 2014 Sep;60(9):1200-8
pubmed: 24987111
Clin Chem. 2010 Jun;56(6):998-1006
pubmed: 20378769
Virology. 2014 Jan 5;448:210-6
pubmed: 24314651
Br J Cancer. 2012 Apr 24;106(9):1526-34
pubmed: 22472886
Bone. 2012 Jan;50(1):171-81
pubmed: 22037351
Orphanet J Rare Dis. 2013 Jan 11;8:7
pubmed: 23311495
N Z Vet J. 1994 Oct;42(5):180-4
pubmed: 16031776
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W478-83
pubmed: 22573175
J Vet Intern Med. 2019 Jan;33(1):241-250
pubmed: 30506726
Br J Cancer. 2010 Aug 24;103(5):693-700
pubmed: 20683447
Acta Vet Scand. 1995;36(2):223-36
pubmed: 7484549
Cancer. 2013 Jan 1;119(1):72-80
pubmed: 22736309
Vet Q. 2016 Dec;36(4):189-196
pubmed: 27327513
Cancer Res. 2004 Jun 1;64(11):3878-84
pubmed: 15172997
Nat Protoc. 2013 Sep;8(9):1765-86
pubmed: 23975260
J Am Vet Med Assoc. 2013 Jan 1;242(1):99-104
pubmed: 23234288
Br J Cancer. 2011 Mar 1;104(5):830-40
pubmed: 21326242
EMBO Mol Med. 2012 Mar;4(3):143-59
pubmed: 22351564
Clin Cancer Res. 2013 Apr 15;19(8):2154-62
pubmed: 23459718
PLoS One. 2011;6(10):e25114
pubmed: 22053178
J Gen Virol. 2011 Apr;92(Pt 4):773-83
pubmed: 21177927
J Vet Diagn Invest. 2006 Jan;18(1):123-6
pubmed: 16566271
J Biol Chem. 2011 Sep 2;286(35):30706-13
pubmed: 21737452
Neuro Oncol. 2010 May;12(5):422-33
pubmed: 20406893
BMC Med Genomics. 2015 Oct 14;8:61
pubmed: 26462558
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W317-22
pubmed: 19465387
Vet Immunol Immunopathol. 1988 Oct;19(3-4):215-23
pubmed: 3252614
Vet Comp Oncol. 2017 Sep;15(3):764-774
pubmed: 27039895
Methods. 2010 Apr;50(4):237-43
pubmed: 20079844
Mol Cancer. 2012 Jul 02;11:44
pubmed: 22747855
Clin Cancer Res. 2014 Jun 15;20(12):3107-17
pubmed: 24833665
Acta Vet Scand. 2016 Jun 29;58(1):44
pubmed: 27356979
Biomol Detect Quantif. 2017 Dec 18;15:1-5
pubmed: 29276692
Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9
pubmed: 18458333
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
mBio. 2017 Jan 3;8(1):
pubmed: 28049151
Vet Comp Oncol. 2018 Mar;16(1):37-46
pubmed: 28220614
Expert Opin Investig Drugs. 2009 Jan;18(1):45-56
pubmed: 19053881
Cancer Med. 2016 Jul;5(7):1619-28
pubmed: 27109697
PLoS One. 2012;7(9):e46045
pubmed: 23029380
BMC Biotechnol. 2009 Dec 21;9:102
pubmed: 20025722
Cancer Cell. 2006 Jun;9(6):435-43
pubmed: 16766263
Vet J. 2014 Jan;199(1):68-71
pubmed: 24152383
Nat Rev Genet. 2009 Oct;10(10):704-14
pubmed: 19763153
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4
pubmed: 16381832
J Pathol. 2010 Jan;220(1):71-86
pubmed: 19768731
Biochimie. 2017 Jun;137:20-28
pubmed: 28259757
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Br J Cancer. 2012 Aug 7;107(4):684-94
pubmed: 22805332
Nucleic Acids Res. 2015 Jan;43(Database issue):D153-9
pubmed: 25416803
Res Vet Sci. 2000 Dec;69(3):295-300
pubmed: 11124103